Santhera Announces H1 2025 Financial Results & Updates
Santhera reported a 70% year-on-year revenue jump to CHF 24 million for the first half of 2025 as Agamree...
Genfit H1 2025 Financial Results & Company Activity Update
Genfit reported first-half 2025 results and a strategic refocus in liver disease. The company ended June with €107.5 million...
Benitec Biopharma Reports Full Year 2025 Financial Results
Benitec Biopharma reported full-year 2025 results and advanced its lead program, announcing an independent data safety monitoring board recommendation...
Semnur, Denali Capital Complete Business Combination
Semnur Pharmaceuticals has closed its business combination with Denali Capital Acquisition Corp, creating a publicly traded entity that will...
API, Mitacs Launch New Life Science Placement Program Kick-off
Applied Pharmaceutical Innovation has launched the Life Sciences Placement Program in partnership with Mitacs, aiming to place 1,000 paid...
Angelini Pharma Inks Innovative Brain Health Asset Agreement
Angelini Pharma has secured an exclusive global option to develop and commercialize SVG105, a preclinical antisense oligonucleotide targeting the...
Promising Data: Cytisinicline for COPD Smoking Cessation
Achieve Life Sciences reported new peer-reviewed data showing its investigational agent, cytisinicline, significantly improved continuous abstinence rates versus placebo...
Cosmos Health Launches in $164B U.S. Nutraceuticals Market
Cosmos Health has launched its U.S. operations with the debut of Sky Premium Life Noor Collagen, a marine collagen...
Immutep, GWU Cancer Center Launch Neoadjuvant Efti Study
Immutep has initiated an investigator-initiated Phase II trial of eftilagimod alfa (efti) as a neoadjuvant therapy in early-stage HR+/HER2-negative...
Intellia’s Promising Longer-Term Nex-Z Data for ATTR Emerge
Intellia Therapeutics will present longer-term data from its ongoing Phase 1 trial of Nexiguran ziclumeran (Nex-Z), an investigational in...